Aristidis Veves, D.Sc., M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetic Foot | 65 | 2024 | 380 | 13.580 |
Why?
|
| Diabetic Neuropathies | 75 | 2021 | 405 | 10.040 |
Why?
|
| Wound Healing | 50 | 2024 | 2799 | 5.900 |
Why?
|
| Diabetes Mellitus, Experimental | 16 | 2024 | 1115 | 4.440 |
Why?
|
| Skin | 37 | 2023 | 4474 | 2.650 |
Why?
|
| Microcirculation | 29 | 2016 | 1269 | 2.560 |
Why?
|
| Diabetic Angiopathies | 25 | 2020 | 804 | 2.410 |
Why?
|
| Diabetes Mellitus | 31 | 2023 | 5835 | 2.350 |
Why?
|
| Vasodilation | 20 | 2013 | 961 | 2.060 |
Why?
|
| Foot | 27 | 2009 | 574 | 1.980 |
Why?
|
| Endothelium, Vascular | 29 | 2016 | 4430 | 1.520 |
Why?
|
| Diabetes Mellitus, Type 2 | 47 | 2021 | 12127 | 1.480 |
Why?
|
| Bandages | 9 | 2024 | 269 | 1.320 |
Why?
|
| Alginates | 3 | 2022 | 248 | 1.320 |
Why?
|
| Foot Ulcer | 12 | 2023 | 63 | 1.310 |
Why?
|
| Skin Ulcer | 7 | 2019 | 129 | 1.280 |
Why?
|
| Diabetes Mellitus, Type 1 | 31 | 2016 | 3439 | 1.210 |
Why?
|
| Brachial Artery | 11 | 2010 | 366 | 1.140 |
Why?
|
| Foreign-Body Reaction | 2 | 2024 | 157 | 1.060 |
Why?
|
| Neuropeptides | 4 | 2019 | 944 | 1.010 |
Why?
|
| Vascular Diseases | 4 | 2016 | 1161 | 0.910 |
Why?
|
| Inflammation Mediators | 6 | 2013 | 1886 | 0.880 |
Why?
|
| Vasodilator Agents | 11 | 2013 | 973 | 0.800 |
Why?
|
| Skin, Artificial | 3 | 2011 | 89 | 0.780 |
Why?
|
| Forearm | 13 | 2013 | 427 | 0.720 |
Why?
|
| Hypoglycemic Agents | 5 | 2020 | 3076 | 0.710 |
Why?
|
| Diabetes Complications | 7 | 2016 | 1317 | 0.690 |
Why?
|
| Prostheses and Implants | 2 | 2024 | 1272 | 0.690 |
Why?
|
| Autonomic Pathways | 1 | 2019 | 31 | 0.680 |
Why?
|
| Continuous Positive Airway Pressure | 3 | 2020 | 575 | 0.660 |
Why?
|
| Sleep Apnea, Obstructive | 6 | 2020 | 1870 | 0.650 |
Why?
|
| Cytokines | 10 | 2024 | 7377 | 0.650 |
Why?
|
| Iontophoresis | 11 | 2009 | 74 | 0.640 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 2 | 2016 | 311 | 0.630 |
Why?
|
| Nitroprusside | 10 | 2009 | 272 | 0.620 |
Why?
|
| Interleukin-10 | 1 | 2024 | 1176 | 0.610 |
Why?
|
| Autonomic Nervous System | 3 | 2020 | 701 | 0.600 |
Why?
|
| Exosomes | 1 | 2022 | 424 | 0.570 |
Why?
|
| Ventricular Function, Left | 4 | 2020 | 3876 | 0.560 |
Why?
|
| MicroRNAs | 2 | 2024 | 3796 | 0.550 |
Why?
|
| Blood Vessels | 4 | 2013 | 1113 | 0.550 |
Why?
|
| Regional Blood Flow | 12 | 2013 | 1487 | 0.550 |
Why?
|
| Debridement | 5 | 2022 | 493 | 0.550 |
Why?
|
| Mast Cells | 4 | 2020 | 1391 | 0.550 |
Why?
|
| Vibration | 14 | 2009 | 328 | 0.530 |
Why?
|
| Valine | 2 | 2009 | 408 | 0.520 |
Why?
|
| Ventricular Function, Right | 1 | 2020 | 618 | 0.520 |
Why?
|
| Diabetic Nephropathies | 2 | 2022 | 973 | 0.510 |
Why?
|
| Chromans | 3 | 2005 | 117 | 0.510 |
Why?
|
| Laser-Doppler Flowmetry | 11 | 2013 | 239 | 0.500 |
Why?
|
| Physical Stimulation | 2 | 2009 | 518 | 0.480 |
Why?
|
| Muscle, Skeletal | 5 | 2016 | 4923 | 0.480 |
Why?
|
| Phosphocreatine | 2 | 2013 | 261 | 0.480 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 2 | 2009 | 431 | 0.480 |
Why?
|
| Amides | 2 | 2016 | 450 | 0.470 |
Why?
|
| Substance P | 2 | 2015 | 335 | 0.470 |
Why?
|
| Analgesics | 2 | 2020 | 1070 | 0.460 |
Why?
|
| Rabbits | 7 | 2024 | 4780 | 0.460 |
Why?
|
| Collagen | 4 | 2006 | 2637 | 0.450 |
Why?
|
| Humans | 168 | 2024 | 760437 | 0.450 |
Why?
|
| Acetylcholine | 11 | 2009 | 628 | 0.440 |
Why?
|
| Immunity, Cellular | 1 | 2019 | 1559 | 0.440 |
Why?
|
| Middle Aged | 98 | 2024 | 220382 | 0.440 |
Why?
|
| Glucagon-Like Peptide 1 | 2 | 2013 | 363 | 0.430 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 1517 | 0.420 |
Why?
|
| Reflex | 4 | 2005 | 376 | 0.420 |
Why?
|
| Mitochondrial Diseases | 1 | 2016 | 344 | 0.410 |
Why?
|
| Thiazolidinediones | 3 | 2005 | 461 | 0.410 |
Why?
|
| Fumarates | 1 | 2013 | 131 | 0.410 |
Why?
|
| Cardiovascular System | 1 | 2020 | 835 | 0.400 |
Why?
|
| Heptanoic Acids | 2 | 2004 | 344 | 0.400 |
Why?
|
| Sensory Thresholds | 13 | 2009 | 377 | 0.390 |
Why?
|
| Tetrazoles | 2 | 2009 | 907 | 0.390 |
Why?
|
| Inflammation | 10 | 2016 | 10746 | 0.390 |
Why?
|
| Neural Conduction | 17 | 2014 | 441 | 0.390 |
Why?
|
| Peripheral Vascular Diseases | 3 | 2009 | 488 | 0.390 |
Why?
|
| Regeneration | 1 | 2020 | 1508 | 0.380 |
Why?
|
| Animals | 40 | 2024 | 168253 | 0.380 |
Why?
|
| Fibroblasts | 7 | 2022 | 4106 | 0.380 |
Why?
|
| Indoles | 1 | 2019 | 1833 | 0.380 |
Why?
|
| Reference Values | 16 | 2016 | 4921 | 0.370 |
Why?
|
| Pressure | 14 | 2004 | 1155 | 0.370 |
Why?
|
| Dermatitis | 1 | 2013 | 200 | 0.370 |
Why?
|
| Macrophages | 5 | 2022 | 5764 | 0.370 |
Why?
|
| Kidney Function Tests | 1 | 2013 | 675 | 0.370 |
Why?
|
| Oxidative Phosphorylation | 1 | 2013 | 497 | 0.360 |
Why?
|
| Vascular Endothelial Growth Factors | 2 | 2010 | 748 | 0.360 |
Why?
|
| Pain Measurement | 5 | 2014 | 3546 | 0.360 |
Why?
|
| Vascular Surgical Procedures | 4 | 2009 | 1490 | 0.360 |
Why?
|
| Male | 105 | 2024 | 360035 | 0.350 |
Why?
|
| Wound Infection | 2 | 2010 | 243 | 0.350 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2020 | 3486 | 0.350 |
Why?
|
| Biocompatible Materials | 3 | 2024 | 1689 | 0.350 |
Why?
|
| Neurophysiology | 1 | 2010 | 144 | 0.340 |
Why?
|
| Ischemia | 4 | 2013 | 1876 | 0.340 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 4 | 2014 | 1649 | 0.330 |
Why?
|
| Female | 98 | 2024 | 391875 | 0.320 |
Why?
|
| Aged | 62 | 2024 | 168840 | 0.320 |
Why?
|
| Neuralgia | 2 | 2014 | 611 | 0.310 |
Why?
|
| Mice | 21 | 2024 | 81402 | 0.300 |
Why?
|
| Forefoot, Human | 3 | 2016 | 31 | 0.300 |
Why?
|
| Pyrroles | 2 | 2004 | 1126 | 0.300 |
Why?
|
| Muscle, Smooth, Vascular | 2 | 2013 | 1492 | 0.290 |
Why?
|
| Bilirubin | 1 | 2009 | 437 | 0.280 |
Why?
|
| Stockings, Compression | 1 | 2006 | 36 | 0.280 |
Why?
|
| Diuresis | 2 | 2004 | 106 | 0.280 |
Why?
|
| Skin Care | 1 | 2006 | 57 | 0.270 |
Why?
|
| Lactoferrin | 1 | 2007 | 100 | 0.270 |
Why?
|
| Adult | 69 | 2021 | 220781 | 0.270 |
Why?
|
| Stem Cells | 2 | 2022 | 3522 | 0.260 |
Why?
|
| Oxygen Consumption | 5 | 2007 | 1859 | 0.260 |
Why?
|
| Leg | 3 | 2002 | 1089 | 0.260 |
Why?
|
| Osteomyelitis | 1 | 2010 | 407 | 0.260 |
Why?
|
| Peripheral Nerves | 5 | 2014 | 479 | 0.250 |
Why?
|
| Oxidative Stress | 4 | 2016 | 3108 | 0.250 |
Why?
|
| Axons | 6 | 2006 | 1673 | 0.240 |
Why?
|
| Hormones, Ectopic | 1 | 2004 | 37 | 0.240 |
Why?
|
| Oxygen | 5 | 2023 | 4222 | 0.240 |
Why?
|
| Microvessels | 1 | 2009 | 574 | 0.240 |
Why?
|
| Poly(ADP-ribose) Polymerases | 2 | 2003 | 427 | 0.230 |
Why?
|
| Streptozocin | 2 | 2023 | 193 | 0.230 |
Why?
|
| Insulin | 5 | 2016 | 6591 | 0.230 |
Why?
|
| Sensation | 2 | 2003 | 337 | 0.230 |
Why?
|
| Chemokine CX3CL1 | 1 | 2024 | 63 | 0.230 |
Why?
|
| Blood Circulation | 1 | 2005 | 249 | 0.230 |
Why?
|
| Drug Delivery Systems | 1 | 2015 | 2224 | 0.220 |
Why?
|
| Nicotinic Acids | 1 | 2003 | 31 | 0.220 |
Why?
|
| Case-Control Studies | 13 | 2016 | 22097 | 0.220 |
Why?
|
| Water | 4 | 2024 | 1409 | 0.220 |
Why?
|
| Sural Nerve | 7 | 2001 | 105 | 0.220 |
Why?
|
| Interleukin-5 | 1 | 2024 | 269 | 0.220 |
Why?
|
| Blood Flow Velocity | 6 | 2013 | 1370 | 0.210 |
Why?
|
| Microscopy, Fluorescence, Multiphoton | 3 | 2020 | 267 | 0.210 |
Why?
|
| Foot Diseases | 7 | 1993 | 147 | 0.210 |
Why?
|
| Pain | 6 | 2009 | 5075 | 0.210 |
Why?
|
| Perception | 5 | 2003 | 1196 | 0.210 |
Why?
|
| Clothing | 4 | 2009 | 97 | 0.210 |
Why?
|
| National Institute of Diabetes and Digestive and Kidney Diseases (U.S.) | 1 | 2022 | 26 | 0.210 |
Why?
|
| Cellulose, Oxidized | 1 | 2002 | 12 | 0.210 |
Why?
|
| Nitric Oxide Synthase | 3 | 2003 | 906 | 0.210 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2024 | 4355 | 0.210 |
Why?
|
| Nerve Fibers, Unmyelinated | 1 | 2003 | 98 | 0.210 |
Why?
|
| Tissue Adhesives | 1 | 2024 | 173 | 0.210 |
Why?
|
| Adiponectin | 2 | 2005 | 1113 | 0.200 |
Why?
|
| Endothelial Cells | 2 | 2022 | 3541 | 0.200 |
Why?
|
| Emollients | 1 | 2002 | 41 | 0.200 |
Why?
|
| Shoes | 5 | 2009 | 94 | 0.200 |
Why?
|
| Joints | 3 | 2004 | 321 | 0.200 |
Why?
|
| Foot Dermatoses | 1 | 2002 | 47 | 0.200 |
Why?
|
| Interleukin-8 | 2 | 2024 | 696 | 0.200 |
Why?
|
| Therapies, Investigational | 1 | 2023 | 111 | 0.200 |
Why?
|
| Nervous System | 1 | 2005 | 543 | 0.200 |
Why?
|
| Risk Factors | 24 | 2022 | 74055 | 0.200 |
Why?
|
| Interleukin-13 | 1 | 2024 | 375 | 0.200 |
Why?
|
| Exercise | 3 | 2013 | 5874 | 0.190 |
Why?
|
| Peripheral Arterial Disease | 1 | 2013 | 1271 | 0.190 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 3 | 2006 | 691 | 0.190 |
Why?
|
| Aorta | 1 | 2009 | 2042 | 0.190 |
Why?
|
| Keratinocytes | 3 | 2022 | 790 | 0.190 |
Why?
|
| Culture Media, Conditioned | 1 | 2022 | 522 | 0.180 |
Why?
|
| Biopsy | 7 | 2013 | 6765 | 0.180 |
Why?
|
| Cell Movement | 4 | 2020 | 5198 | 0.180 |
Why?
|
| Cross-Sectional Studies | 12 | 2020 | 26063 | 0.180 |
Why?
|
| Cytochrome P-450 CYP1A1 | 1 | 2020 | 90 | 0.180 |
Why?
|
| Vitamin E | 1 | 2005 | 871 | 0.180 |
Why?
|
| Flavin-Adenine Dinucleotide | 1 | 2020 | 31 | 0.170 |
Why?
|
| Interleukin-4 | 1 | 2024 | 1130 | 0.170 |
Why?
|
| Atrophy | 1 | 2005 | 1631 | 0.170 |
Why?
|
| Neurologic Examination | 8 | 2013 | 916 | 0.170 |
Why?
|
| Urea | 1 | 2002 | 444 | 0.170 |
Why?
|
| Organic Anion Transporters | 1 | 2020 | 101 | 0.170 |
Why?
|
| Tyrosine | 2 | 2010 | 1438 | 0.170 |
Why?
|
| Peripheral Nervous System | 2 | 2005 | 151 | 0.170 |
Why?
|
| Cell Adhesion Molecules | 3 | 2022 | 1600 | 0.170 |
Why?
|
| Anesthetics, Local | 2 | 2003 | 998 | 0.170 |
Why?
|
| Mitochondria | 1 | 2013 | 3624 | 0.170 |
Why?
|
| Hemostatics | 1 | 2002 | 241 | 0.170 |
Why?
|
| Treatment Outcome | 14 | 2020 | 64591 | 0.170 |
Why?
|
| Hot Temperature | 3 | 2003 | 1440 | 0.170 |
Why?
|
| Aged, 80 and over | 20 | 2020 | 58859 | 0.160 |
Why?
|
| Sequence Analysis, RNA | 3 | 2024 | 2018 | 0.160 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2004 | 3243 | 0.160 |
Why?
|
| Vasomotor System | 1 | 1999 | 207 | 0.160 |
Why?
|
| Antioxidants | 1 | 2007 | 1670 | 0.160 |
Why?
|
| Peroneal Nerve | 10 | 1998 | 76 | 0.160 |
Why?
|
| Vascular Patency | 1 | 2002 | 904 | 0.160 |
Why?
|
| Thiazoles | 2 | 2003 | 1513 | 0.160 |
Why?
|
| Obesity | 6 | 2014 | 12918 | 0.160 |
Why?
|
| Endothelial Growth Factors | 1 | 2001 | 673 | 0.160 |
Why?
|
| Prediabetic State | 1 | 2004 | 549 | 0.160 |
Why?
|
| Blood Proteins | 1 | 2024 | 1174 | 0.160 |
Why?
|
| Prospective Studies | 12 | 2024 | 54339 | 0.150 |
Why?
|
| Polysomnography | 4 | 2020 | 1839 | 0.150 |
Why?
|
| Administration, Topical | 3 | 2007 | 703 | 0.150 |
Why?
|
| Fibrosis | 2 | 2024 | 2048 | 0.150 |
Why?
|
| Blood Glucose | 8 | 2013 | 6380 | 0.150 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2013 | 2272 | 0.150 |
Why?
|
| Lymphokines | 1 | 2001 | 927 | 0.150 |
Why?
|
| Wounds and Injuries | 1 | 2011 | 2483 | 0.150 |
Why?
|
| Papaverine | 2 | 2013 | 45 | 0.140 |
Why?
|
| Hyperemia | 1 | 1998 | 221 | 0.140 |
Why?
|
| Evidence-Based Medicine | 2 | 2008 | 3685 | 0.140 |
Why?
|
| Disease Progression | 6 | 2014 | 13484 | 0.140 |
Why?
|
| Nitroglycerin | 3 | 2009 | 329 | 0.140 |
Why?
|
| Double-Blind Method | 6 | 2009 | 12320 | 0.140 |
Why?
|
| Electrophysiology | 5 | 2013 | 1263 | 0.140 |
Why?
|
| Orthotic Devices | 2 | 2006 | 129 | 0.140 |
Why?
|
| Lactic Acid | 1 | 2002 | 1134 | 0.140 |
Why?
|
| Prognosis | 7 | 2024 | 29551 | 0.140 |
Why?
|
| Cardiovascular Diseases | 2 | 2016 | 15476 | 0.130 |
Why?
|
| Follow-Up Studies | 11 | 2016 | 39078 | 0.130 |
Why?
|
| Transforming Growth Factor beta | 2 | 2022 | 1959 | 0.130 |
Why?
|
| Leg Ulcer | 2 | 1996 | 71 | 0.130 |
Why?
|
| Estrogen Replacement Therapy | 2 | 1999 | 1208 | 0.130 |
Why?
|
| NAD | 1 | 2020 | 614 | 0.130 |
Why?
|
| Predictive Value of Tests | 5 | 2024 | 15257 | 0.130 |
Why?
|
| Protein Kinase C-delta | 1 | 2016 | 114 | 0.130 |
Why?
|
| Skin Transplantation | 1 | 2001 | 1083 | 0.130 |
Why?
|
| Interferon-gamma | 1 | 2024 | 3157 | 0.130 |
Why?
|
| Hexuronic Acids | 1 | 2015 | 145 | 0.120 |
Why?
|
| Glucuronic Acid | 1 | 2015 | 150 | 0.120 |
Why?
|
| Interleukin-6 | 2 | 2024 | 3209 | 0.120 |
Why?
|
| Phosphorus | 1 | 2016 | 336 | 0.120 |
Why?
|
| Mice, Inbred C57BL | 8 | 2024 | 22121 | 0.120 |
Why?
|
| Receptors, Neurokinin-1 | 1 | 2015 | 134 | 0.120 |
Why?
|
| Transplantation, Heterologous | 1 | 2023 | 2385 | 0.120 |
Why?
|
| Sleep Deprivation | 1 | 2021 | 840 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 2 | 2023 | 7424 | 0.110 |
Why?
|
| Gels | 1 | 2015 | 419 | 0.110 |
Why?
|
| Tolazoline | 1 | 2013 | 4 | 0.110 |
Why?
|
| Time Factors | 9 | 2024 | 39947 | 0.110 |
Why?
|
| Israel | 1 | 2016 | 722 | 0.110 |
Why?
|
| Single-Cell Analysis | 2 | 2022 | 2413 | 0.110 |
Why?
|
| Disease Models, Animal | 8 | 2024 | 18216 | 0.110 |
Why?
|
| Podiatry | 1 | 1993 | 28 | 0.110 |
Why?
|
| Skin Absorption | 1 | 2013 | 94 | 0.110 |
Why?
|
| Calcium Channel Blockers | 1 | 2016 | 694 | 0.110 |
Why?
|
| Calcium Channels | 1 | 2016 | 620 | 0.110 |
Why?
|
| Tissue Engineering | 2 | 2015 | 1870 | 0.110 |
Why?
|
| Epidermis | 1 | 2016 | 528 | 0.100 |
Why?
|
| Energy Metabolism | 2 | 2009 | 2875 | 0.100 |
Why?
|
| Neurons, Afferent | 1 | 1995 | 498 | 0.100 |
Why?
|
| Kidney Medulla | 2 | 2004 | 169 | 0.100 |
Why?
|
| Physical Examination | 3 | 2010 | 1254 | 0.100 |
Why?
|
| C-Reactive Protein | 3 | 2010 | 3822 | 0.100 |
Why?
|
| Fibronectins | 1 | 2016 | 723 | 0.100 |
Why?
|
| Amputation Stumps | 1 | 1992 | 38 | 0.100 |
Why?
|
| Osteoprotegerin | 1 | 2013 | 176 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2020 | 36362 | 0.100 |
Why?
|
| Piperazines | 1 | 2003 | 2519 | 0.100 |
Why?
|
| Negative-Pressure Wound Therapy | 1 | 2014 | 154 | 0.100 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2012 | 96 | 0.100 |
Why?
|
| Ibuprofen | 1 | 2013 | 229 | 0.100 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2016 | 1066 | 0.100 |
Why?
|
| Cross-Over Studies | 2 | 2009 | 2073 | 0.100 |
Why?
|
| Extracellular Matrix | 2 | 2016 | 1725 | 0.100 |
Why?
|
| Forecasting | 1 | 2020 | 2925 | 0.090 |
Why?
|
| Erectile Dysfunction | 1 | 1995 | 444 | 0.090 |
Why?
|
| Administration, Cutaneous | 2 | 2013 | 712 | 0.090 |
Why?
|
| Ulcer | 2 | 2023 | 204 | 0.090 |
Why?
|
| Sex Characteristics | 1 | 2021 | 2633 | 0.090 |
Why?
|
| Drug Carriers | 1 | 2015 | 706 | 0.090 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2016 | 710 | 0.090 |
Why?
|
| Nerve Fibers | 2 | 2011 | 708 | 0.090 |
Why?
|
| Body Mass Index | 7 | 2014 | 12932 | 0.090 |
Why?
|
| Polyneuropathies | 1 | 2011 | 137 | 0.090 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2013 | 629 | 0.090 |
Why?
|
| Nitric Oxide Synthase Type III | 2 | 2003 | 704 | 0.090 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2012 | 591 | 0.090 |
Why?
|
| Aspirin | 1 | 2002 | 3134 | 0.090 |
Why?
|
| Bioengineering | 1 | 2011 | 99 | 0.090 |
Why?
|
| Solubility | 3 | 2003 | 1091 | 0.090 |
Why?
|
| Hyperglycemia | 1 | 1998 | 1371 | 0.090 |
Why?
|
| Probability | 2 | 2006 | 2476 | 0.090 |
Why?
|
| Heart Rate | 3 | 1998 | 4190 | 0.080 |
Why?
|
| Cohort Studies | 7 | 2021 | 41366 | 0.080 |
Why?
|
| Incidence | 4 | 2013 | 21322 | 0.080 |
Why?
|
| Diabetic Cardiomyopathies | 1 | 2010 | 90 | 0.080 |
Why?
|
| Albuminuria | 3 | 2005 | 650 | 0.080 |
Why?
|
| Nitrosation | 1 | 2009 | 25 | 0.080 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 2010 | 1125 | 0.080 |
Why?
|
| Microbiological Techniques | 1 | 2010 | 98 | 0.080 |
Why?
|
| Molecular Imaging | 1 | 2016 | 814 | 0.080 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2012 | 632 | 0.080 |
Why?
|
| Cannabidiol | 1 | 2010 | 118 | 0.080 |
Why?
|
| Calcitonin | 1 | 2010 | 329 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2007 | 10759 | 0.080 |
Why?
|
| Movement | 3 | 2009 | 1478 | 0.080 |
Why?
|
| Young Adult | 7 | 2020 | 59068 | 0.080 |
Why?
|
| Kidney | 1 | 2004 | 7046 | 0.080 |
Why?
|
| von Willebrand Factor | 3 | 2006 | 673 | 0.080 |
Why?
|
| Demography | 1 | 2013 | 1648 | 0.080 |
Why?
|
| Gastric Inhibitory Polypeptide | 1 | 2008 | 68 | 0.080 |
Why?
|
| Mass Screening | 2 | 2010 | 5424 | 0.080 |
Why?
|
| Cysteine Endopeptidases | 1 | 2010 | 548 | 0.080 |
Why?
|
| Muscle Contraction | 1 | 2013 | 1197 | 0.080 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2024 | 8163 | 0.070 |
Why?
|
| Chemokines | 1 | 2012 | 960 | 0.070 |
Why?
|
| Sodium Chloride | 2 | 2002 | 588 | 0.070 |
Why?
|
| Metatarsophalangeal Joint | 2 | 2002 | 41 | 0.070 |
Why?
|
| Touch Perception | 1 | 2009 | 106 | 0.070 |
Why?
|
| Stochastic Processes | 1 | 2009 | 356 | 0.070 |
Why?
|
| Incretins | 1 | 2008 | 99 | 0.070 |
Why?
|
| Adamantane | 1 | 2008 | 148 | 0.070 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2010 | 322 | 0.070 |
Why?
|
| Body Temperature Regulation | 1 | 2009 | 292 | 0.070 |
Why?
|
| Immunohistochemistry | 4 | 2016 | 11070 | 0.070 |
Why?
|
| Blood Gas Monitoring, Transcutaneous | 1 | 2006 | 34 | 0.070 |
Why?
|
| Boston | 4 | 2012 | 9326 | 0.070 |
Why?
|
| Biopsy, Needle | 2 | 2016 | 1626 | 0.070 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2018 | 1857 | 0.070 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2016 | 3765 | 0.070 |
Why?
|
| Reproducibility of Results | 4 | 2024 | 20078 | 0.070 |
Why?
|
| Pyrrolidines | 1 | 2008 | 338 | 0.070 |
Why?
|
| Cholinergic Fibers | 1 | 2006 | 69 | 0.070 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 1 | 2008 | 170 | 0.070 |
Why?
|
| Ultrasonography, Doppler | 2 | 1998 | 461 | 0.070 |
Why?
|
| Ventricular Remodeling | 1 | 2014 | 1264 | 0.070 |
Why?
|
| Medical History Taking | 1 | 2010 | 773 | 0.070 |
Why?
|
| Ultrasonography | 3 | 2010 | 5966 | 0.070 |
Why?
|
| Reflex, Abnormal | 1 | 2006 | 83 | 0.070 |
Why?
|
| Cold Temperature | 1 | 2010 | 786 | 0.070 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 1993 | 1496 | 0.070 |
Why?
|
| Rats | 4 | 2024 | 23712 | 0.060 |
Why?
|
| Leukocyte Count | 1 | 2010 | 1596 | 0.060 |
Why?
|
| Down-Regulation | 1 | 2013 | 2911 | 0.060 |
Why?
|
| Risk Assessment | 4 | 2013 | 23953 | 0.060 |
Why?
|
| Myocardial Ischemia | 1 | 2016 | 2110 | 0.060 |
Why?
|
| Regression Analysis | 2 | 2010 | 6340 | 0.060 |
Why?
|
| Ubiquitin | 1 | 2010 | 838 | 0.060 |
Why?
|
| Chronic Disease | 3 | 2011 | 9309 | 0.060 |
Why?
|
| Protein Precursors | 1 | 2010 | 1134 | 0.060 |
Why?
|
| Phosphates | 1 | 2009 | 770 | 0.060 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2014 | 972 | 0.060 |
Why?
|
| Research Design | 1 | 2021 | 6168 | 0.060 |
Why?
|
| Age Factors | 3 | 2020 | 18379 | 0.060 |
Why?
|
| Sensitivity and Specificity | 4 | 2016 | 14661 | 0.060 |
Why?
|
| Apolipoproteins E | 1 | 2010 | 1444 | 0.060 |
Why?
|
| Tritium | 1 | 2005 | 707 | 0.060 |
Why?
|
| Fasting | 2 | 2003 | 1600 | 0.060 |
Why?
|
| Consensus | 1 | 2014 | 3115 | 0.060 |
Why?
|
| Blood Pressure | 5 | 2009 | 8479 | 0.060 |
Why?
|
| Endothelium | 1 | 2007 | 765 | 0.060 |
Why?
|